Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells1

In this study, we investigated whether mesenchymal stem cells (MSC) had immunomodulatory properties in solid organ allotransplantation, using a semiallogeneic heart transplant mouse model, and studied the mechanism(s) underlying MSC tolerogenic effects. Either single (portal vein, day −7) or double (portal vein, day −7 and tail vein, day −1) pretransplant infusions of donor-derived B6C3 MSC in B6 recipients induced a profound T cell hyporesponsiveness and prolonged B6C3 cardiac allograft survival. The protolerogenic effect was abrogated when donor-derived MSC were injected together with B6C3 hematopoietic stem cells (HSC), suggesting that HSC negatively impact MSC immunomodulatory properties. Both the induction (pretransplant) and the maintenance phase (>100 days posttransplant) of donor-derived MSC-induced tolerance were associated with CD4+CD25+Foxp3+ Treg expansion and impaired anti-donor Th1 activity. MSC-induced regulatory T cells (Treg) were donor-specific since adoptive transfer of splenocytes from tolerant mice prevented the rejection of fully MHC-mismatched donor-specific secondary allografts but not of third-party grafts. In addition, infusion of recipient-derived B6 MSC tolerized a semiallogeneic B6C3 cardiac allograft, but not a fully MHC-mismatched BALB/c graft, and expanded Treg. A double i.v. pretransplant infusion of recipient-derived MSC had the same tolerogenic effect as the combined intraportal/i.v. MSC infusions, which makes the tolerogenic protocol applicable in a clinical setting. In contrast, single MSC infusions given either peritransplant or 1 day after transplant were less effective. Altogether these findings indicate that MSC immunomodulatory properties require HSC removal, partial sharing of MHC Ags between the donor and the recipient and pretransplant infusion, and are associated with expansion of donor-specific Treg.

[1]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[2]  A. Tabilio,et al.  Mesenchymal cells recruit and regulate T regulatory cells. , 2008, Experimental hematology.

[3]  J. Rossignol,et al.  A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. , 2007, Blood.

[4]  N. Mao,et al.  Functional and Phenotypic Alteration of Intrasplenic Lymphocytes Affected by Mesenchymal Stem Cells in a Murine Allosplenocyte Transfusion Model , 2007, Cell transplantation.

[5]  Shiqiang Yu,et al.  Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. , 2006, Transplantation proceedings.

[6]  B. John,et al.  Cellular and molecular mechanisms of liver tolerance , 2006, Immunological reviews.

[7]  X. Chen,et al.  Mesenchymal stem cells in immunoregulation , 2006, Immunology and cell biology.

[8]  M. Yacoub,et al.  Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. , 2006, Tissue engineering.

[9]  R. Willemze,et al.  Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells1 , 2006, The Journal of Immunology.

[10]  Anoop P. Patel,et al.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. , 2006, Blood.

[11]  G. Koehl,et al.  Immunomodulatory Effects of Mesenchymal Stem Cells in a Rat Organ Transplant Model , 2006, Transplantation.

[12]  Mamoru Ito,et al.  Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. , 2006, Blood.

[13]  T. Strom,et al.  Specificity of CD4+CD25+ Regulatory T Cell Function in Alloimmunity1 , 2006, The Journal of Immunology.

[14]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[15]  Frank P Barry,et al.  Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.

[16]  Megan Sykes,et al.  Organ transplantation—how much of the promise has been realized? , 2005, Nature Medicine.

[17]  G. Remuzzi,et al.  Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells , 2005, Transplantation.

[18]  R. Cancedda,et al.  Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway , 2005, European journal of immunology.

[19]  O. Ringdén,et al.  Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. , 2005, Experimental cell research.

[20]  E. Lam,et al.  Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. , 2005, Blood.

[21]  D. Mevorach,et al.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.

[22]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[23]  T. Asahara,et al.  Liver sinusoidal endothelial cells contribute to alloreactive T‐cell tolerance induced by portal venous injection of donor splenocytes , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  L. Turka,et al.  Tregs and transplantation tolerance. , 2004, The Journal of clinical investigation.

[25]  N. Perico,et al.  Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[26]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[27]  A. Benabid,et al.  Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. , 2004, Experimental cell research.

[28]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[29]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[30]  P. Rameshwar,et al.  Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens1 , 2003, The Journal of Immunology.

[31]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[32]  D. Greiner,et al.  Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. , 2003, The Journal of clinical investigation.

[33]  Robert A. Kloner,et al.  Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted Myocardium: Feasibility, Cell Migration, and Body Distribution , 2003, Circulation.

[34]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[35]  C. Cobbs,et al.  Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. , 2003, Blood.

[36]  J. Mosca,et al.  Characterization and functionality of cell surface molecules on human mesenchymal stem cells. , 2003, Journal of biomedical science.

[37]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[38]  R. Lechler,et al.  The complementary roles of deletion and regulation in transplantation tolerance , 2003, Nature Reviews Immunology.

[39]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[40]  Li Zhang,et al.  Donor-lymphocyte infusion induces transplantation tolerance by activating systemic and graft-infiltrating double-negative regulatory T cells. , 2002, Blood.

[41]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[43]  D. Ganten,et al.  Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning , 2002, Nature Medicine.

[44]  M. Karim,et al.  CD25+CD4+ Regulatory T Cells Prevent Graft Rejection: CTLA-4- and IL-10-Dependent Immunoregulation of Alloresponses1 , 2002, The Journal of Immunology.

[45]  G. Remuzzi,et al.  Challenges to achieving clinical transplantation tolerance. , 2001, The Journal of clinical investigation.

[46]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[47]  R. Hoffman,et al.  Role of mesenchymal stem cells in hematopoietic stem cell transplantation , 2000, Current opinion in hematology.

[48]  A. Monaco,et al.  Donor MHC Class II Antigen Is Essential for Induction of Transplantation Tolerance by Bone Marrow Cells1 , 2000, The Journal of Immunology.

[49]  M. Sykes,et al.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment , 2000, Nature Medicine.

[50]  N. Perico,et al.  Peripheral donor leukocytes prolong survival of rat renal allografts. , 1999, Kidney international.

[51]  Gene Kopen,et al.  Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: Variations in yield, growth, and differentiation , 1999, Journal of cellular biochemistry.

[52]  S. Ikehara,et al.  A strategy for organ allografts without using immunosuppressants or irradiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Ikehara,et al.  Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: Possible explanation for the mechanism of tolerance induction by portal vein injection , 1994, European journal of immunology.

[54]  D. Kioussis,et al.  "Infectious" transplantation tolerance , 1993, Science.

[55]  M. W. Flye,et al.  Intrathymic Injection of Donor Alloantigens Induces Donor‐specific Vascularized Allograft Tolerance Without Immunosuppression , 1992, Annals of surgery.

[56]  R. Gorczynski,et al.  Specific manipulation in vivo of immunity to skin grafts bearing multiple minor histocompatibility differences. , 1991, Immunology letters.

[57]  M. W. Flye,et al.  Kupffer cell blockade prevents induction of portal venous tolerance in rat cardiac allograft transplantation. , 1990, The Journal of surgical research.

[58]  R. Corry,et al.  PRIMARILY VASCULARIZED ALLOGRAFTS OF HEARTS IN MICE: THE ROLE OF H‐2D, H‐2K, AND NON‐H-2 ANTIGENS IN REJECTION , 1973, Transplantation.

[59]  O. Joffre,et al.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes , 2008, Nature Medicine.

[60]  Kazuya Sato,et al.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.

[61]  J. Stagg.  Immune regulation by mesenchymal stem cells: two sides to the coin. , 2007, Tissue antigens.

[62]  R. Willemze,et al.  Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34 -Derived and Monocyte-Derived Dendritic Cells , 2006 .

[63]  M. Noris,et al.  Natural versus adaptive regulatory T cells. , 2005, Contributions to nephrology.

[64]  A. Cometa,et al.  Inherited thrombocytopenias: from genes to therapy , 1994 .

[65]  池袋 一哉.  Treatment of streptozotocin-induced diabetes mellitus by transplantation of islet cells plus bone marrow cells via portal vein in rats , 2003 .

[66]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.